Skip to main content

Table 1 Baseline clinical characteristics, laboratory coagulation and thromboelastography parameters on admission to the intensive care unit

From: The evolution of clot strength in critically-ill COVID-19 patients: a prospective observational thromboelastography study

Variable on admission

Reference ranges

Total

(N = 40)

30-day Survivor

(N = 13)

30-day

Non-survivor (N = 27)

P value

Age, years (SD)

 

55 (±8)

52 (±9)

56 (±8)

0.09

Sex

    

0.08

 Female n (%)

 

14 (35)

7 (54)

7 (26)

 

 Male n (%)

 

26 (65)

6 (46)

20 (74)

 

Comorbidities

 Hypertension n (%)

 

28 (70)

9 (69)

19 (70)

0.94

 Diabetes n (%)

 

27 (68)

8 (62)

19 (70)

0.58

BMI (kg/m2)

    

0.02

 Normal weight (18–24.9) n (%)

 

6 (15)

0 (0)

6 (22)

 

 Overweight (25–29.9) n (%)

 

13 (33)

2 (15)

11 (41)

 

 Obese (> 30) n (%)

 

21 (52)

11 (85)

10 (37)

 

Disease Severity Scores

 SOFA score (IQR)

 

4 (4–6)

4 (4–4)

4 (4–6)

0.55

 Pa02/Fi02 ratio (IQR)

200 > − ≤ 300 Mild ARDS

100 > − ≤ 200 Moderate ARDS

≤ 100 Severe ARDS

95(64–124)

95 (60–103)

96 (66–130)

0.61

 DIC score (IQR)

< 5 not suggestive of DIC

≥ 5 is suggestive of DIC

3 (2–3)

3 (2–3)

3 (2–4)

0.55

Laboratory Values

 Platelet count, ×  109/L (IQR)

171–388

354 (267–448)

352 (263–466)

356 (270–438)

0.86

 Urea, mmol/L (IQR)

2.1–7.1

9.5 (7.3–11.6)

7.7 (5.8–8.5)

10.2 (9.1–13.0)

0.02

 Creatinine, μmol/L (IQR)

64–104

72 (61.5–117.0)

67 (64–81)

85 (61–136)

0.32

 Prothrombin time, s (IQR)a

11–12.5

13.7 (13.0–15.3)

13.3 (12.8–13.5)

14.2 (13.2–15.7)

1.00

 Activated partial thromboplastin time, s (IQR)

25.1–36.5

30.1 (28.6–32.8)

29.9 (28.9–32.6)

30.2 (28.4–32.8)

1.00

 D-Dimer, mg/L (IQR)

< 0.25

1.2 (0.6–3.1)

0.9 (0.6–2.5)

1.4 (0.6–4.0)

1.00

 Fibrinogen, g/L (IQR)

2–4

5 (5–5)b

5 (5–5)b

5 (5–5)b

0.59

TEG Heparinase

 R-time, min (IQR)

4.3–8.3

7.7 (5.8–9.8)

7.7 (7.5–8.2)

7.8 (5.8–10.7)

0.87

 K-time, min (IQR)

0.8–1.9

1.1 (0.9–1.7)

1.1 (0.9–1.4)

1.2 (0.9–1.8)

0.46

 α-angle, degree (IQR)

64–77

75.4 (69.6–77.9)

75.0 (71.3–78.9)

75.9 (69.6–77.9)

0.87

 Maximum amplitude, mm (IQR)

52–68

70.3 (68.5–72.1)

71.1 (69.5–72.6)

70.2 (68.5–71.7)

0.30

 LY-30, % (IQR)

0–8

0 (0)

0 (0–0.1)

0 (0)

0.70

TEG Functional Fibrinogen

 Maximum amplitude, mm (IQR)

15–32

47.0 (41.2–52.6)

48.3 (41.4–50.4)

44.9 (40.2–52.6)

0.88

  1. Table 1. Demographics, laboratory coagulation studies and thromboelastography (TEG) results for all study patients on admission to the intensive care unit (ICU). Differences between admission characteristics for overall 30-day survivors (N = 13) and non-survivors (N = 27) are shown with corresponding p-values. Data are reported as mean (±SD), median (IQR), n (%). Reference ranges were established by the local laboratory and TEG 6 s operating manual.
  2. BMI Body mass index, SOFA Sequential organ failure assessment, Pa02/Fi02 Ratio of arterial oxygen partial pressure to fractional inspired oxygen, DIC Disseminated intravascular coagulopathy, PT Prothrombin time, aPTT Activated partial thromboplastin time 
  3. aPT laboratory control for the duration of the study was 11.7 s
  4. bValue is above the upper measurable limit of fibrinogen in local laboratory
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us